GTBP GT Biopharma, Inc.
Healthcare$0.44+1.62%ClosedMarket Cap: $4.7M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
1.76
P/S
0.00
EV/EBITDA
0.32
DCF Value
$1.11
FCF Yield
-282.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-901.3%
ROA
-477.5%
ROIC
-205.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-2.8M | $-2.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-5.6M | $-23.0M | $— | — |
| FY null | $0.00 | NaN% | $-12.4M | $-28.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-3.4M | $8.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-1.5M | $-30.2M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.9M | $-776.0K | $— | — |
| Q4 null | $0.00 | NaN% | $-3.8M | $-3.8M | $— | — |
| FY null | $0.00 | NaN% | $-14.4M | $-13.2M | $— | — |
| Q3 null | $0.00 | NaN% | $-3.6M | $-3.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-3.9M | $-3.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-3.1M | $-2.3M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-3.2M | $-3.0M | $-2.15 | — |